Cipla Share Price
52 Week Range
- Open Price
- Previous Close
Start SIP in CIPLAStart SIP
Cipla Investment Rating
Cipla has an operating revenue of Rs. 21,634.18 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 16% is great, ROE of 12% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 15% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 8% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 115 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
|Indicator||Jun 2022||Mar 2022||Dec 2021||Sep 2021||Jun 2021||Mar 2021|
|Oper Rev Qtr Cr||3,070||2,882||3,955||3,859||3,948||3,173|
|Operating Expenses Qtr Cr||2,300||2,559||2,915||2,952||2,872||2,583|
|Operating Profit Qtr Cr||857||388||1,040||983||1,145||650|
|Depreciation Qtr Cr||107||117||134||139||137||137|
|Interest Qtr Cr||2||6||6||8||8||9|
|Tax Qtr Cr||221||105||243||252||288||140|
|Net Profit Qtr Cr||759||653||731||782||792||413|
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Cipla Resistance and Support
|MACD Single Line||20.72|
Cipla Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Cipla Result Highlights
NSE-Medical-Generic DrugsCipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13091.79 Cr. and Equity Capital is Rs. 161.36 Cr. for the Year ended 31/03/2022. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
|Shares in Float||54.07|
|No of funds||1234|
|U/D Vol ratio||1.3|
|LTDebt / Equity|
|Foreign Portfolio Investors||27.64%||26.64%||24.35%|
|Financial Institutions/ Banks||0.04%||0.04%||0.11%|
|Dr. Y K Hamied||Chairman|
|Mr. M K Hamied||Vice Chairman|
|Ms. Samina Hamied||Executive Vice Chairman|
|Mr. Umang Vohra||Managing Director & Global CEO|
|Mr. S Radhakrishnan||Non Exe.Non Ind.Director|
|Mr. Ashok Sinha||Independent Director|
|Mr. P R Ramesh||Independent Director|
|Mr. Robert Stewart||Independent Director|
|Dr. Peter Mugyenyi||Independent Director|
|Mr. Adil Zainulbhai||Independent Director|
|Ms. Punita Lal||Independent Director|
|Dr. Mandar Vaidya||Independent Director|
What is Share Price of Cipla ?
Cipla share price is ₹1130 As on 07 October, 2022 | 17:59
What is the Market Cap of Cipla ?
The Market Cap of Cipla is ₹91231.5 Cr As on 07 October, 2022 | 17:59
What is the P/E ratio of Cipla ?
The P/E ratio of Cipla is 36.4 As on 07 October, 2022 | 17:59
What is the PB ratio of Cipla ?
The PB ratio of Cipla is 4.3 As on 07 October, 2022 | 17:59
Is it the right time to invest in Cipla?
Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.
Is Cipla an Indian company?
Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.
Who is the CEO of Cipla?
Umang Vohra has been the CEO of Cipla since 1 September 2016.
What is Cipla's stock price CAGR?
Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.
How to buy Cipla Ltd. shares?
You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.
What is the ROE of Cipla Ltd.?
The Return on Equity of the stock is 13.5% as of March 2022.